Evidence-Based Medicine
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7813-7823
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7813
Figure 5
Figure 5 Incremental cost-effectiveness ratio outcome in patients with negative celiac serology. A: Parameters that affected the incremental cost-effectiveness ratio (ICER) analysis; B: A one way sensitivity analysis of ICER in regards to the cost of small bowel biopsies. CD: Celiac disease; GFD: Gluten free diet.